In addition, Hayek et al, recently showed that BRAF-inhibitors (Vemurafenib and Dabrafenib) upregulate IL-1β release by mouse and human dendritic cells, thus resulting in enhanced dendritic cell-mediated anti-tumor immune responses [71]. Here, BRAF is linked to neoplasm.